Premium
BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL)
Author(s) -
Chen R.,
Gibb A.L.,
Collins G.P.,
Popat R.,
ElSharkawi D.,
Burton C.,
Lewis D.,
Miall F.M.,
Forgie A.,
Compagi A.,
Andreola G.,
Brar S.,
Thall A.,
Woolfson A.,
Radford J.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_54
Subject(s) - avelumab , medicine , blockade , refractory (planetary science) , oncology , immune checkpoint , antibody , lymphoma , gastroenterology , immunology , cancer , immunotherapy , nivolumab , biology , receptor , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom